2011 - Transplantomics and Biomarkers in Transplantation


Long Term Outcomes (CR/Tol)

3.3 - B Cell Profile In Operationally Tolerant Kidney Recipients

Presenter: Sophie, Brouard, Nantes, France
Authors: Sophie Brouard


B Cell Profile In Operationally Tolerant Kidney Recipients

Sophie Brouard, Centre Hospitalier Universitaire Hotel Dieu, Nantes, France

Although the achievement of immunological tolerance has been possible in animal models, the translation into the clinic is not feasible yet and remains highly experimental in human. Nevertheless, evidence have been accumulated that some transplant recipients permanently accept their grafts in the absence of immunosuppression. Up to 20% of liver recipients can withdraw immunosuppression and some cases in kidney transplantation have been observed. Since several years, efforts have been made in the scientific community to enroll large cohort of such rare patients. We and others have reported that operationally tolerant recipients were characterized by a high number of peripheral B cells with a specific B cell profile associated with an increase in B cell populations expressing CD5 and CD1d protein and transitional B cell markers. Transcripts for BANK1, a negative modulator of CD40-mediated AKT activation and a hypo responsive cytokine profile were also increased, suggesting an inhibitory blood B cell profile in patients with operational tolerance. Altogether these data show that blood B cell phenotype and key molecules of B cell regulation are regulated in operationally tolerant recipients. We will make the point on the different studies published recently.


You must be logged in to view recordings

Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Our Corporate Sponsors

TTS gratefully acknowledges the Corporate Partners whose generous support makes the work of the Society possible:

  • astellas
  • roche
  • sanofi